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Abdominal aortic aneurysms (AAA) are characterized by
pathological remodeling of the aortic extracellular matrix
(ECM). However, besides the well-characterized elastoly-
sis and collagenolysis little is known about changes in
other ECM proteins. Previous proteomics studies on AAA
focused on cellular changes without emphasis on the
ECM. In the present study, ECM proteins and their deg-
radation products were selectively extracted from aneu-
rysmal and control aortas using a solubility-based sub-
fractionation methodology and analyzed by gel-liquid
chromatography-tandem MS and label-free quantitation.
The proteomics analysis revealed novel changes in the
ECM of AAA, including increased expression as well as
degradation of collagen XII, thrombospondin 2, aortic
carboxypeptidase-like protein, periostin, fibronectin
and tenascin. Proteomics also confirmed the accumu-
lation of macrophage metalloelastase (MMP-12). Incu-
bation of control aortic tissue with recombinant MMP-12
resulted in the extensive fragmentation of these glyco-
proteins, most of which are novel substrates of MMP-12.
In conclusion, our proteomics methodology allowed the
first detailed analysis of the ECM in AAA and identified
markers of pathological ECM remodeling related to
MMP-12 activity. Molecular & Cellular Proteomics 10:
10.1074/mcp.M111.008128, 1–15, 2011.
Abdominal aortic aneurysms (AAA)1 affect 2–10% of the
elderly population (1, 2) and are histopathologically charac-
terized by the extensive degeneration of the aortic extracel-
lular matrix (ECM) (3). The breakdown of structural proteins, in
particular medial elastin and collagen I and III, is responsible
for the inability of the aortic wall to withstand the hemody-
namic forces (4). Transmural inflammatory infiltrates (5) com-
bined with a reduction in the number of medial smooth muscle
cells trigger the destruction of the aortic connective tissue via
unregulated proteinase activity (6, 7). However, apart from the
well-established elastolysis and collagenolysis, little is known
about other changes in ECM composition and turnover in
AAA. Recent proteomics studies on aneurysms have used
whole tissue lysates (8, 9) and reported significant changes in
cellular proteins but provided limited insights into matrix re-
modeling. Regarding the ECM these approaches had several
limitations: first, whole tissue lysates are rich in cellular pro-
teins, which mask the identification of scarce extracellular
components, including proteinases and proteinase inhibitors.
Second, ECM proteins are difficult to solubilize and analyze
by proteomics because of their unique biochemical properties
(aggregation, cross-linking, and glycosylation). Third, during
pathological processes, such as aneurysm formation, the
ECM undergoes extensive turnover with continuous degrada-
tion as well as deposition of newly synthesized matrix pro-
teins. In analysis of whole tissue lysates, newly synthesized
ECM proteins cannot be readily discerned from existing ma-
trix proteins and only abundant degradation products are
detected (9). To overcome these shortcomings we have re-
cently developed a solubility-based, protein subfractionation
procedure, which facilitates the selective extraction of newly
synthesized ECM proteins and degradation products, re-
duces the contamination with cellular proteins, and ensures
the solubilization of the interstitial ECM and its associated
proteins, thereby improving their analysis by proteomics (10).
In this study, we applied this subfractionation method to AAA.
Our aim was to characterize the changes in ECM and asso-
ciated proteins involved in the pathological remodeling proc-
ess. We achieved the most detailed proteomics characteriza-
tion of the aneurysmal ECM to date and revealed major
differences between healthy and AAA tissues including the
increased deposition and fragmentation of collagen XII,
thrombospondin 2, aortic carboxypeptidase-like protein
(ACLP), periostin, and fibronectin. In addition, we were able to
show that these glycoproteins are novel proteolytic targets of
MMP-12. Thus, our proteomics approach can serve as a
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platform for the identification of candidate markers of patho-
logical remodeling in clinical samples (11).
EXPERIMENTAL PROCEDURES
Source of Tissue—This study was approved by the Research Eth-
ics Committees of King’s College London and St. George’s Hospital
London. All patients gave written informed consent. Advanced, as-
ymptomatic, infrarenal AAA specimens were collected from four male
patients65 yr of age during open aneurysm repair surgery based on
aneurysm size exceeding 5.5 cm in diameter (representative hema-
toxylin and eosin stained sections are shown in supplemental Fig. S1).
Four control samples from patients without connective tissue disorder
(one female and three males aged 20 to 55) were obtained upon
aortotomy performed during routine aortic valve replacement from
positions of the ascending aorta that were free of macroscopically
evident vascular pathology (supplemental Fig. S1). There were no
known potential confounders during sampling of clinical specimens
and tissues were immediately snap-frozen and kept in liquid nitrogen
for later use.
Tissue Preparation—Before extraction the tissue specimens were
partially thawed and weighed. Approximately 150 mg of tissue per
aortic sample were placed in ice-cold phosphate buffered saline to
remove plasma contaminants. The buffer was supplemented with 1%
v/v proteinase inhibitor mixture (Sigma-Aldrich), which contains
AEBSF, aprotinin, bestatin, E-64, leupeptin, and pepstatin, with a
broad specificity for serine, cysteine, and acid proteinases, and
aminopeptidases and 1% v/v phosphatase inhibitor mixture (Sigma-
Aldrich), which contains, sodium orthovanadate, cantharidin, imidaz-
ole, and calyculin A, to inhibit a broad range of phosphatases. In
addition, 25 mM EDTA were added to ensure inhibition of metallopro-
teinases. While the tissue samples were immersed in the cold saline,
they were diced with a scalpel into 8–10 smaller pieces to facilitate
the removal of plasma contaminants and the effective extraction of
extracellular proteins as described below.
Three-step Extraction Methodology—For the proteomics method-
ology we used three healthy aortic specimens (CON) and four AAA
specimens. The diced samples were first incubated in a 0.5 M NaCl,
10 mM Tris, pH 7.5 buffer supplemented with proteinase and phos-
phatase inhibitor cocktails as above and 25 mM EDTA. The volume of
the buffer was adjusted to 10:1 of the tissue weight (i.e. 100 mg in 1
ml). The samples were mildly vortexed for 4 h at room temperature.
The NaCl extracts were then desalted with centrifugation using de-
salting columns (Zeba Spin, Pierce Biotechnology, Cramlington,
Northumberland, UK). After desalting the extracts were mixed with
100% acetone (5:1 volume ratio) at 20 °C for 16 h. Proteins were
precipitated with centrifugation (16,000 g for 45 min) and the pellets
were vacuum-dried and redissolved in deglycosylation buffer (see
below). Subsequently, the aortic samples were incubated with 0.08%
SDS (10:1 buffer volume to tissue weight), including proteinase and
phosphatase inhibitor cocktails and 25 mM EDTA. The samples were
mildly vortexed, to minimize mechanical disruption of the ECM, for 4 h
at room temperature. The SDS solution was then removed and stored
frozen for later use. Finally, the samples were incubated in a 4 M
guanidine-HCl, 50 mM sodium acetate pH 5.8 buffer (5:1 buffer vol-
ume to tissue weight), plus proteinase and phosphatase inhibitor
cocktails and 25 mM EDTA. pH was adjusted to 5.8 to improve the
extractability of vascular proteoglycans (12). The samples were incu-
bated for 48 h at room temperature and vortexed vigorously to
enhance the mechanical disruption of matrix proteins. After the de-
naturing extraction guanidine was removed by mixing the samples
with 100% ethanol (5:1 volume ratio) at 20 °C for 16 h. Proteins
were then precipitated with centrifugation (16,000 g for 45 min) and
the pellets were washed with 90% ethanol, dried, and redissolved in
deglycosylation buffer.
Deglycosylation—Deglycosylation (removal of glycosaminoglycan
side chains) of the different extracts was achieved in a 150 mM NaCl,
50 mM sodium acetate pH 6.8 buffer supplemented with proteinase
inhibitors and 10 mM EDTA for 16 h at 37 °C. The deglycosylation
enzymes (0.05 U) were: 1) chondroitinase ABC from Proteus vulgaris
(catalyzes the removal of polysaccharides containing 134--D-hexos-
aminyl and 133--D-glucuronosyl or 133--L-iduronosyl linkages to
disaccharides containing 4-deoxy--D-gluc-4-enuronosyl groups. It
acts on chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan
sulfate glycosaminoglycan side chains). One unit will liberate 1.0 M
of 2-acetamido-2-deoxy-3-O-(-D-gluc-4-ene-pyranosyluronic acid)-
4-O-sulfo-D-galactose from chondroitin sulfate A or 1.0 M of 2-
acetamido-2-deoxy-3-O-(-D-gluc-4-ene-pyranosyluronic acid)-6-O-
sulfo-D-galactose from chondroitin sulfate C per minute at pH 8.0 at
37 °C. 2) keratanase from Bacteroides fragillis (cleaves internal 134-
-galactose linkages in unbranched, repeating poly-N-acetyl-lac-
tosamine and keratan sulfate). One unit will release 1.0 M of reducing
sugar per minute at 37 °C and pH 5.8 from bovine corneal keratan
sulfate. 3) heparatinase II Flavobacterium heparinum (cleaves heparan
sulfate). One unit forms 0.1 M of unsaturated uronic acid per hour at
pH 7.0 at 37 °C. All enzymes were purchased from Sigma-Aldrich.
After, deglycosylation the solutions were clarified with centrifugation
(16.000  g for 10 min) to ensure that the samples were free of
turbidity and protein concentration was estimated by UV absorbance
at 280 nm. Because of the expected contamination with nucleic acids
that remain in the tissue after decellularization, in the 4 M guanidine
extracts we used the Groves equation [(A280  1.55) – (A260  0.76)]
to account for nucleic acid interference (13).
One-dimensional Electrophoresis—The 0.5 M NaCl and 4 M guani-
dine extracts were denatured and reduced in sample buffer contain-
ing 100 mM Tris, pH 6.8, 40% glycerol, 0.2% SDS, 2% -mercapto-
ethanol and 0.02% bromphenol blue and boiled at 96 °C for 10 min.
Thirty-five micrograms of protein per sample were loaded and sepa-
rated on Bis-Tris discontinuous 4–12% polyacrylamide gradient gels
(NuPage, Invitrogen). Protein standards were run along side the sam-
ples (prestained All Blue, Precision Plus, Bio-Rad Laboratories, Cram-
lington, Northumberland, UK).
Nanoflow LC-MS/MS—After electrophoresis, gels were stained us-
ing the PlusOne Silver staining Kit (GE Healthcare). Silver staining was
used for band staining to avoid cross-contamination with fainter gel
bands (14) All gel bands were excised in identical parallel positions
across lanes and no empty gel pieces were left behind. Subsequently,
all gel bands were subjected to in-gel tryptic digestion using an
Investigator ProGest (Genomic Solutions) robotic digestion system.
Tryptic peptides were separated on a nanoflow LC system (Dionex
UltiMate 3000, UK) and eluted with a 10 min gradient (10–25% B in
35 min, 25–40% B in 5 min, 90% B in 10 min, and 2% B in 30 min
where A is 2% acetonitrile, 0.1% formic acid in high performance
liquid chromatography (HPLC) H2O and B is 90% acetonitrile, 0.1%
formic acid in HPLC H2O). The column (Dionex PepMap C18, 25 cm
length, 75 m internal diameter, 3 m particle size) was coupled to
a nanospray source (Picoview) using RePlay (Advion). After the
direct liquid chromatography (LC)-MS run, the flow was switched
and the portion stored in the capillary of the RePlay device re-
analyzed (“replay run”) (15). Spectra were collected from a high-
mass accuracy analyzer (LTQ Orbitrap XL, ThermoFisher Scientific)
using full ion scan mode over the mass-to-charge (m/z) range
450–1600. Tandem MS (MS/MS) was performed on the top six ions
in each MS scan using the data-dependent acquisition mode with
dynamic exclusion enabled. MS/MS peaklists were generated by
extract_msn.exe and matched to human database (UniProtKB/
Swiss-Prot Release 14.6, 20333 protein entries) using SEQUEST
v.28 (rev. 13), (Bioworks Browser 3.3.1 SP1, ThermoFisher Scien-
tific) and X! Tandem, (Version 2007.01.01.2). Carboxyamidomethyl-
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ation of cysteine was chosen as fixed modification and oxidation of
methionine as variable modification. The mass tolerance was set at
1.5 AMU for the precursor ions and at 1.0 AMU for fragment ions.
Two missed cleavages were allowed. Scaffold (version 2.0.6, Pro-
teome Software Inc., Portland, OR) was used to calculate the
normalized spectral counts, and to validate peptide and protein
identifications (16, 17). According to the default values in the Scaf-
fold software, peptide identifications were accepted if they could be
established at greater than 95.0% probability as specified by the
Peptide Prophet algorithm (16). Only tryptic peptides were included
in the analysis. Protein identifications were accepted if they could
be established at greater than 99.0% probability (17) with at least
two independent peptides and a mass accuracy of 10ppm of the
precursor ion. ECM proteins identified for the first time by proteom-
ics in the vasculature as well as ECM proteins with low spectral
counts were further examined to ensure the quality of the identified
spectra.
Western Blotting—Aliquots of the NaCl, guanidine, and SDS ex-
tracts were mixed with denaturing sample buffer and boiled. Thirty
micrograms of protein per sample were loaded and separated on
4–12% gradient gels as above. Proteins were then transferred on
nitrocellulose membranes. Membranes were blocked in 5% fat-free
milk powder in PBS and probed for 16 h at 4 °C with primary anti-
bodies to: CD68 (sc-70761, Santa Cruz Biotechnology, Santa Cruz,
CA) and smooth muscle actin (A5228, Sigma-Aldrich) (0.08% SDS
extracts). Collagen XII (sc-166020), thrombospondin 2 (sc-12313),
fibronectin (sc-56391), ACLP (sc-32919), periostin (sc-67233), and
MMP-12 (sc-133151) all from Santa Cruz Biotechnology, and tenas-
cin (ab6393) and TIMP-1 (ab38978) both from Abcam (Cambridge,
UK) (0.5 M NaCl extracts). The 4 M guanidine extracts were immuno-
blotted for eSOD (SOD-105) from Stressgen (Victoria, BC, Canada).
All antibodies were used at 1:500 dilution in 5% bovine serum albu-
min. The membranes were treated with the appropriate secondary,
horseradish peroxidase (HRP) conjugated antibodies (Dako) at a
1:2000 dilution. Finally, the blots were imaged using enhanced che-
milluminenscence (ECL, GE Healthcare) and films were developed on
an Xograph processor. The densitometry for the lanes from devel-
oped films for collagen XII, tenascin, thrombospondin 2, fibronectin,
ACLP, periostin, eSOD, MMP-12, and TIMP-1 was measured using
the ImageJ software (v1.42q, NIH, USA).
In Vitro MMP Digestion Assay—Normal aortic specimens taken
upon aortotomy (as described above) from patients without connec-
tive tissue disorder, were dissected into equal blocks (30 mg), and
were washed five times in ice-cold, 1 PBS. The tissue blocks were
then mixed with 10 volumes MMP reaction buffer (10 mM CaCl2, 120
mM NaCl, 50 mM Trizma base, and 0.05%w/v Brij-35, pH 7.5), which
was either used plain or supplemented with human recombinant
MMP-9 or human recombinant MMP-12, both derived from murine
myeloma cell lines (R&D Systems, Minneapolis, MN). MMP-9 was
activated by incubation with 0.5 mM APMA (Aminophenylmercuric
acetate) (Sigma-Aldrich) in MMP reaction buffer at 37 °C for 24 h,
while MMP-12 was auto-activated in MMP reaction buffer at 37 °C
for 30 h, both according to manufacturer’s instructions. APMA was
removed by desalting through a Zeba Spin (Thermo Scientific)
desalting column (MMP-12 was also spun through a desalting
column for comparison). The mixtures were supplemented with the
proteinase inhibitor mixture to inhibit non-MMP proteinase activity.
After the incubation of the aortic tissue with the activated MMPs,
the tissue supernatants were deglycosylated, and then immuno-
blotted using antibodies to collagen XII, thrombospondin 2, tenas-
cin, fibronectin ACLP, and periostin. Activated MMP-12 was also
used on human recombinant periostin and thrombospondin 2 both
derived from murine myeloma cell lines (R&D Systems) and on
purified human fibronectin (Sigma-Aldrich). Ten micrograms of
each protein were incubated in MMP reaction buffer, supplemented
with proteinase inhibitor mixture, at 37 °C for 16 h with or without
MMP-12.
Histochemistry—Small representative pieces from AAA and control
aortic samples were placed in OCT compound (BD Healthcare) and
used to generate consecutive 7 m thick sections on a Leica cryostat.
The sections were air-dried (30 min) and fixed in 100% acetone for 20
min. Subsequently, sections were either stained with hematoxylin and
eosin (H&E) or incubated with primary antibodies. Before immunohis-
tochemistry, the internal peroxidase activity was quenched using a
3% hydrogen peroxide solution in methanol for 15 min. Sections were
probed with antibodies to CD68 (sc-70761), ACLP (sc-32919),
MMP-12 (sc-133151) from Santa Cruz Biotechnology. Primary anti-
bodies were used at 2 g/ml. Staining was produced using appro-
priate HRP-conjugated secondary antibodies, developed with di-
aminobenzidine purchased from Dako. Negative controls were
generated with mouse and rabbit isotype IgG antibodies (Sigma-
Aldrich, 2 g/ml). Nuclei were counterstained blue using Mayer’s
hematoxylin solution (Sigma-Aldrich) for 5 min. Images were taken by
a Zeiss Axioplan 2ie microscope interfaced to AxioVision software
(version 3.0.6).
Statistical Analysis—For each clinical sample (CON, n  3 and
AAA, n  4) and biochemical fraction (0.5 M NaCl and 4 M guanidine),
we obtained a technical LC-MS/MS replicate using the RePlay device
(Advion). The value reported as spectral count for each protein was
calculated as the average S.E. of all samples and technical repli-
cates (i.e. CON, n  6 and AAA, n  8). All assigned spectra for each
protein were used for spectral counting. Before statistical analysis
protein spectral counts were normalized using the Scaffold software
(version 2.0.6, Proteome Software Inc., Portland, OR) by calculating
and averaging the number of identified spectra in each sample, then
multiplying the number of spectra assigned to each protein by the
ratio of the average spectral count and the number of total spectra in
that sample. Protein ambiguity issues were handled using tools avail-
able in the Scaffold software and peptides assigned to more than one
protein are highlighted in supplemental Table S1. The difference in
normalized spectral counts for each identified extracellular protein
between control and AAA was computed using two-tailed, unpaired t
test (GraphPad Prism 5). A p value of 0.05 was considered signifi-
cant. Only proteins identified with at least two unique peptides were
included in the analysis and no outliers were removed. Proteins with
a significant difference in normalized spectral counts (p  0.05)
between control and AAA samples were progressively joined into
clusters. Pairwise similarity in spectral counts between different pro-
teins (rows) and different samples (columns) was computed using
Pearson Correlation Coefficient. The dendrograms and quantitative
heat maps were produced using the GenePattern software (version
3.2.3) (18). The relative difference in normalized spectral counts is
represented by a color gradient. No outliers were removed. The
correlation between the spectral counts and the densitometry values
of immunoblots was calculated using Spearman’s rank correlation
coefficient (GraphPad Prism 5). A p value of 0.05 was considered
significant.
RESULTS
Characterization of AAA and ECM Extraction—Before pro-
teomics, all tissue specimens were examined histologically.
Extensive medial degeneration with few intact elastic laminae,
inflammatory infiltrates (indicated by CD68 staining) and loss
of smooth muscle cells (SMCs) were evident in AAA. Repre-
sentative images are shown in Fig. 1A–C. The macrophage
marker CD68 was not detected in normal aortic specimens
(Fig. 1D). CD68 positivity in AAA inversely correlated to
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smooth muscle actin (SMA) staining (Fig. 1D). The ECM and
its associated proteins were extracted from four AAA and
three control (CON) aortas following our established, proce-
dure (10). The proteomics workflow is summarized in Fig. 2.
Briefly, in the first step the ionic strength of the 0.5 M NaCl
buffer is sufficient to solubilize extracellular proteins that are
weakly bound to the ECM (19), including newly synthesized
ECM proteins (20), which are not heavily cross-linked, degra-
dation products and other proteins present in the extracellular
space. In the second step the samples are decellularized
using 0.08% SDS to reduce the highly abundant cellular pro-
teins. Finally, in the third step the extraction of the mature,
heavily cross-linked ECM (proteoglycans, glycoproteins, and
collagens) is achieved using 4 M guanidine, a strongly dena-
turing agent.
Proteomics Analysis of the 0.5 M NaCl and 4 M Guanidine
Extracts—After deglycosylation, proteins in the 0.5 M NaCl
and 4 M guanidine extracts were separated by one-dimen-
sional SDS-PAGE (supplemental Fig. S2), subjected to in-gel
tryptic digestion, and analyzed by LC-MS/MS using a high
mass accuracy ion trap (LTQ-Orbitrap XL, Thermo Fisher
Scientific) interfaced to the RePlay device (Advion) to obtain a
technical replicate for each biological sample. The entire
MS/MS dataset has been deposited in PRIDE, a public repos-
itory for mass spectrometry data (http://www.ebi.ac.uk/
pride/, accession numbers: 16940–17107). Only proteins
passing stringent identification criteria are listed in
supplemental Tables S2 and S3 (0.5 M NaCl and 4 M guanidine
extracts, respectively). According to the Gene Ontology An-
notation database, 80 nonredundant proteins in the 0.5 M
NaCl (Table I) and 117 nonredundant proteins in the 4 M
guanidine (Table II) fractions were either ECM proteins (pro-
teoglycans, glycoproteins, and collagens) or proteins associ-
ated with the ECM such as secreted proteinases, extracellular
enzymes, growth factors, cytokines, and lipoproteins. Among
the identified extracellular proteins eight were only found in
the 0.5 M NaCl extracts whereas 45 proteins were unique to
the 4 M guanidine extracts (Fig. 3A). As expected, most unique
proteins in the 0.5 M NaCl extracts were secreted factors such
as cathepsin S, eosinophil cationic protein, hepatoma-derived
growth factor, leukocyte elastase inhibitor, and proactivator
polypeptide, whereas the proteins exclusive to the 4 M gua-
nidine extracts were predominantly matrix proteins such as
asporin, cartilage acidic protein 1, link protein, prolargin,
laminins, matrix Gla protein, sclerostin, and collagen V. Inter-
estingly, spectral counts for ECM proteins were significantly
increased in the salt-soluble protein fraction of AAA (p 
0.0001, Fig. 3B). In contrast, in the 4 M guanidine extracts the
spectral counts for ECM proteins (Fig. 3C) as well as the
number of total spectra in either the 0.5 M NaCl or 4 M
guanidine extracts (data not shown) were not significantly
different between control and AAA.
ECM and Associated Proteins in AAA—Differences in rela-
tive protein abundance between control (CON) and AAA were
estimated using normalized spectral counts (Table I and Table
II). No outliers were removed. Details can be found in Exper-
imental Procedures. Hierarchical clustering of the differentially
expressed extracellular proteins in both the NaCl and guani-
dine extracts clearly separated the control and AAA samples
and highlighted major differences in their ECM composition
(Fig. 4). Increased levels of collagens I and VI and the fibril-
associated collagen XII, fibronectin, vitronectin, tenascin (al-
ternative name: tenascin-C), thrombospondins 1 and 2, and
ACLP were observed in the 0.5 M NaCl extracts of AAA (Fig.
4A, Table I). These proteins, excluding ACLP, were also more
abundant in the 4 M guanidine extracts of AAA (Fig. 4B, Table
II) indicating that they are components of the mature, salt-
insoluble aneurysmal ECM. We also noted a decrease in the
spectral counts of the large proteoglycans aggrecan, versi-
can, and perlecan in AAA (Fig. 4B, Table II), perhaps because
of proteolysis at an earlier stage of the disease. The reduction
in perlecan could explain the loss of extracellular superoxide
dismutase (eSOD) (Fig. 4A and 4B, Table I and II) because this
antioxidant enzyme is attached to perlecan and other heparan
sulfate proteoglycans in extracellular space (21). There was
also a reduction in another fibril-associated collagen, type
XIV, and the poorly characterized extracellular proteins, retinal
pigment epithelium spondin (RPE-spondin), dyxin and target
of Nesh-SH3 (Fig. 4B, Table II). Moreover, proteomics identi-
fied scarce extracellular proteins including the calgranulins
S100A8 and A9 (Figs. 4A and 4B, Table I and II), calcium-
binding neutrophil proteins that are involved in macrophage
adhesion and transmigration (22), the tissue inhibitor of met-
alloproteinases 1 (TIMP-1) and macrophage metalloelastase,
FIG. 1. Characterization of clinical specimens. Representative
sections of AAA (A) and control aortas (B) were stained with hema-
toxylin & eosin as well as antibodies against the monocyte/macro-
phage marker CD68 (C). Immunoreactivity appears in brown and
nuclei are counterstained with Mayer’s hematoxylin. Scale bar, 5x:
100 m and 20x: 25 m. D, In the cellular extracts (0.08% SDS) of
AAA, smooth muscle actin (SMA) was inversely correlated to CD68.
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MMP-12 (Figs. 4A and 4B Table I and Table II). Representative
MS/MS spectra from extracellular proteins identified for the
first time by proteomics in the vasculature are shown in
supplemental Fig. S3.
Inflammatory Markers in AAA—Besides a clear distinction
between control and AAA samples, the hierarchical clustering
revealed notable differences among the four AAA specimens
(Figs. 4A and 4B). Proteins involved in inflammation, such as
apolipoprotein D, ceruloplasmin, myeloperoxidase, S100A8,
and A9 were more abundant in samples 1 and 3, whereas the
ECM proteins perlecan, aggrecan, versican, collagen XIV, and
the matrix associated enzyme eSOD were higher in samples 2
and 4 (Figs. 4A and 4B). These differences reflect the cellular
composition observed in the SDS extracts (Fig. 1D). AAA
specimens 1 and 3 had a higher macrophage content explain-
ing the abundance of inflammatory factors whereas the loss of
smooth muscle cells is consistent with the reduction in ECM
components.
Validation of Proteomics and ECM Remodelling—Six gly-
coproteins covering the detectable range of protein abun-
dance in our samples were selected for further validation.
According to spectral counting, collagen XII, tenascin, throm-
bospondin 2, fibronectin, ACLP, and periostin (Fig. 5, left
panels) were increased in the 0.5 M NaCl extracts of the four
AAA specimens. Immunoblotting confirmed higher levels in
AAA (Fig. 5, middle panels). The loss of eSOD as well as the
accumulation of MMP-12 and TIMP-1 were also validated by
immunoblotting. Overall, there was a good correlation
(Spearman correlation, r  0.8, p  0.05) between the
protein abundance estimated by spectral counting and
Western blotting (Fig. 5, right panels). For periostin and
MMP-12 the correlation was not significant because spec-
tral counting is less accurate when protein levels are low
(23). Nonetheless, our methodology allowed the detection
of matrix macromolecules as well as scarce secreted pro-
teins in complex clinical samples.
ECM Remodelling and the Role of MMP-12—The Western
blots presented in Fig. 5 highlight the fragmentation of colla-
gen XII, tenascin, thrombospondin 2, fibronectin, ACLP, and
periostin in the AAA samples. Indeed, detailed examination of
the gel-LC-MS/MS data revealed that a high number of
MS/MS spectra were identified in gel segments below the
expected molecular weight of these proteins (Fig. 6A) con-
firming the presence of proteolytic products in the aneurysmal
tissue. Although various MMPs, including MMP-12, have
been linked to matrix proteolysis during aneurysm formation
(24–26), MMP-12 was the only metalloproteinase that was
significantly increased in our proteomics analysis (Fig. 4). To
investigate the possible relationship between the observed
fragmentation of these glycoproteins and the presence of
MMP-12, we incubated macroscopically normal, human
aortic specimens with recombinant MMP-12 in vitro (Fig.
6B). MMP-9, another metalloproteinase implicated in AAA
pathology (27), served as an additional control. MMP-12
induced extensive fragmentation of fibronectin and cleaved
collagen XII, tenascin, and periostin. Thrombospondin 2
FIG. 2. Proteomics workflow. The methodology is based on a three-step subfractionation of the vascular proteome (A), which enriches
ECM, its associated proteins and degradation products. First, specimens are extracted in 0.5 M NaCl. This buffer solubilizes proteins or protein
fragments that are weakly bound to the ECM, including newly synthesized ECM proteins and degradation products. In addition, secreted
proteinases such as MMPs are also extracted. Second, specimens are decellularized with 0.08% SDS to deplete cellular proteins. Finally, the
salt-insoluble ECM proteins are extracted using 4 M guanidine to solubilize the tightly interacting, cross-linked matrix. In the second stage (B),
the identified MMPs are further investigated by incubating healthy tissue with recombinant enzymes to identify novel proteolytic targets and
characterize their proteolytic activity in disease.
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TABLE I
Extracellular matrix and associated proteins identified by proteomics in the 0.5 M NaCl extracts. aThree biological samples performed with two
technical replicates each (n  6). bFour biological samples performed with two technical replicates each (n  8). cIndicates proteins identified
for the first time by proteomics in the vasculature. ND: none detected
Protein name
Swiss Prot
Accession
MW
(kDa)
Mean
spectraS.E.
CONa
Mean
spectraS.E.
AAAb
p value
(t-test)
Proteoglycans and glycoproteins
Thrombospondin-1 TSP1_HUMAN 129 8  0 238  13 0.0004
Fibronectin FINC_HUMAN 263 26  2 144  4 0.0001
Lumican LUM_HUMAN 38 55  1 67  1 0.1000
Aortic carboxypeptidase-like protein AEBP1_HUMAN 131 38  1 53  1 0.0500
EGF-containing fibulin-like ECM protein 1 FBLN3_HUMAN 55 34  1 50  3 0.1200
Tenascin-X TENX_HUMAN 464 47  3 32  1 0.1200
Versican CSPG2_HUMAN 373 20  1 20  1 0.7600
Tenascin TENA_HUMAN 241 1  0 24  1 0.0004
Mimecan MIME_HUMAN 34 19  0 10  0 0.0001
Perlecan PGBM_HUMAN 469 14  3 8  2 0.0840
Thrombospondin-2 TSP2_HUMAN 130 ND 19  1 0.0003
Fibulin-1 FBLN1_HUMAN 77 9  0 11  0 0.4800
Fibrillin-1 FBN1_HUMAN 312 5  0 11  2 0.4600
Vitronectin VTNC_HUMAN 54 ND 15  1 0.0034
Fibromodulin FMOD_HUMAN 43 9  1 7  0 0.2300
Decorin PGS2_HUMAN 40 2  0 5  0 0.0066
Galectin-1 LEG1_HUMAN 15 5  0 6  0 0.3800
TGF-induced protein ig-h3 BGH3_HUMAN 75 ND 5  0 0.0019
Podocan PODN_HUMAN 69 3  0 2  0 0.1700
Cartilage oligomeric matrix protein COMP_HUMAN 83 1  0 3  0 0.2500
Biglycan PGS1_HUMAN 42 1  0 2  0 0.1600
Fibulin-5 FBLN5_HUMAN 50 3  0 1  0 0.0620
Aggrecan PGCA_HUMAN 250 2  0 1  0 0.0580
Lactadherin MFGM_HUMAN 43 1  0 2  0 0.8300
Galectin-3 LEG3_HUMAN 26 ND 2  0 0.2500
Microfibril-associated glycoprotein 4 MFAP4_HUMAN 29 2  0 1  0 0.4600
Periostin POSTN_HUMAN 93 ND 2  0 0.2300
Adlicanc MXRA5_HUMAN 312 ND 1  0 0.0600
Laminin subunit alpha-5 LAMA5_HUMAN 400 1  0 1  0 0.7100
Spondin-1 SPON1_HUMAN 91 2  0 ND 0.0390
Nidogen-1 NID1_HUMAN 136 1  0 1  0 0.4100
Dermatopontin DERM_HUMAN 24 1  0 1  0 0.6300
ECM-associated proteins
Extracellular superoxide dismutase SODE_HUMAN 26 60  3 19  2 0.0011
Serum amyloid P-component SAMP_HUMAN 25 14  0 38  2 0.0190
Pigment epithelium-derived factor PEDF_HUMAN 46 17  0 29  0 0.0003
Apolipoprotein A-I APOA1_HUMAN 31 7  1 30  1 0.0006
Myeloperoxidase PERM_HUMAN 84 2  0 25  2 0.0045
Latent-transforming growth factor beta-
binding protein 2
LTBP2_HUMAN 195 9  1 12  1 0.1500
Apolipoprotein E APOE_HUMAN 36 3  0 17  1 0.0230
Tetranectin TETN_HUMAN 23 10  0 12  0 0.3500
Procollagen C-endopeptidase enhancer 1 PCOC1_HUMAN 48 8  0 12  1 0.1500
Cathepsin D CATD_HUMAN 45 5  0 9  1 0.4200
Ceruloplasmin CERU_HUMAN 122 2  0 12  1 0.0018
Tryptase beta-1 TRYB1_HUMAN 31 7  1 7  1 0.8600
Clusterin CLUS_HUMAN 52 2  0 12  1 0.0003
Insulin-like growth factor-binding protein 7 IBP7_HUMAN 29 11  0 4  0 0.0004
Apolipoprotein D APOD_HUMAN 21 2  0 9  1 0.0270
Protein S100-A8c S10A8_HUMAN 11 1  0 9  1 0.0110
Secreted frizzled-related protein 3 SFRP3_HUMAN 36 6  0 3  0 0.1800
Calreticulin CALR_HUMAN 48 5  0 5  0 0.9300
Protein S100-A9c S10A9_HUMAN 13 ND 6  1 0.0300
Apolipoprotein A-IV APOA4_HUMAN 45 4  0 4  0 0.8900
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was degraded producing two small cleavage products (20
kDa). In comparison to MMP-9, MMP-12 had more pro-
nounced effects on the degradation of fibronectin, tenascin,
collagen XII, and thrombospondin 2, whereas MMP-9 in-
duced the release of full-length periostin from the aortic
matrix, presumably by limited proteolysis. Intriguingly, treat-
ment with both proteinases resulted in an almost complete
loss of ACLP immunostaining. With the exception of fi-
bronectin (28), all other glycoproteins are novel substrates
for MMP-12. The proteinase had a dose (0–50 pM,
supplemental Fig. S4) and time-dependent (2–16h,
supplemental Fig. S5) effect on these glycoproteins in the
aortic explants. Importantly, its proteolytic effect on the
tissue was almost completely abolished by 10 mM EDTA
(supplemental Fig. S6). In addition, MMP-12 was able to
cleave human recombinant periostin and thrombospondin 2
in vitro (Fig. 6C). Human fibronectin, a known MMP-12
substrate, was used as a positive control.
ACLP and MMP-12—The proteolytic effect of MMP-12 on
ACLP was very pronounced and considering the lack of
knowledge on this collagen-associated glycoprotein (29) in
aneurysms, we sought to examine its localization by immu-
nohistochemistry. In AAA, extracellular ACLP staining was
present both in the hypocellular regions of the media (Fig. 7A),
where tissue architecture is more preserved with intact elastic
laminae and absence of inflammatory infiltrates, and in the
amorphous, inflammatory areas, where connective tissue loss
is evident (Fig. 7B). In consecutive serial sections, MMP-12
staining was predominantly found in the inflammatory areas
(Figs. 7C and 7D) and there was an inverse correlation in the
staining intensity of the two proteins, supporting the proteo-
lytic effect of MMP-12 on ACLP in the tissue. Negative con-
trols are shown in Figs. 7E and 7F.
DISCUSSION
The destruction of the aortic connective tissue in aneurysms
is driven by a severe inflammatory reaction and involves the
excessive degradation of the aortic ECM. However, the abun-
dance of cellular proteins in the aorta and the biochemical
properties of matrix components have so far limited the char-
acterization of the ECM in vascular pathologies (30). In this
study we employed a solubility-based, protein subfractionation
methodology that enabled the detailed characterization of the
ECM and its associated proteins in AAA. Importantly, this ap-
proach offered novel insights into the pathological remodeling
process and allowed us to relate changes in the turnover of
certain ECM proteins to the increased levels of MMP-12 in AAA.
TABLE I—continued
Protein name
Swiss Prot
Accession
MW
(kDa)
Mean
spectraS.E.
CONa
Mean
spectraS.E.
AAAb
p value
(t-test)
Metalloproteinase inhibitor 1 TIMP1_HUMAN 23 1  0 4  0 0.0019
Latent-TGF-binding protein, isoform 1S LTB1S_HUMAN 153 2  0 3  0 0.4800
Cathepsin G CATG_HUMAN 29 1  0 2  0 0.6500
Apolipoprotein B-100 APOB_HUMAN 516 1  0 3  0 0.0220
Leukocyte elastase inhibitor ILEU_HUMAN 43 2  0 2  0 0.7900
Target of Nesh-SH3 TARSH_HUMAN 119 2  0 3  0 0.4100
Carboxypeptidase-like protein X2 CPXM2_HUMAN 86 2  0 1  0 0.9700
Hepatoma-derived growth factor HDGF_HUMAN 27 2  0 1  0 0.0590
Macrophage metalloelastasec MMP12_HUMAN 54 ND 3  0 0.0500
Cathepsin Z CATZ_HUMAN 34 3  0 1  0 0.0250
Proactivator polypeptide SAP_HUMAN 58 3  0 ND 0.0067
Latent-TGF-binding protein 4 LTBP4_HUMAN 173 2  0 ND 0.0600
Secreted frizzled-related protein 1 SFRP1_HUMAN 35 2  0 ND 0.0830
Cathepsin S CATS_HUMAN 37 ND 1  0 0.2300
72 type IV collagenase MMP2_HUMAN 74 1  0 ND 0.1300
Glia-derived nexin GDN_HUMAN 44 ND 1  0 0.2900
Chymase CMA1_HUMAN 27 ND 1  0 0.3000
Eosinophil cationic proteinc ECP_HUMAN 18 ND 1  0 0.5300
Collagens
Collagen alpha-1(XIV) COEA1_HUMAN 194 71  1 50  2 0.0009
Collagen alpha-1(XII) COCA1_HUMAN 333 13  1 81  5 0.0014
Collagen alpha-3(VI) CO6A3_HUMAN 344 13  1 36  3 0.0430
Collagen alpha-1(VI) CO6A1_HUMAN 109 4  0 8  1 0.2000
Collagen alpha-1(XVIII) COIA1_HUMAN 178 5  0 7  0 0.1700
Collagen alpha-2(VI) CO6A2_HUMAN 109 2  0 3  0 0.6100
Collagen alpha-1(I) CO1A1_HUMAN 139 1  0 3  0 0.1900
Collagen alpha-1(XV) COFA1_HUMAN 142 2  0 3  0 0.5600
Collagen alpha-2(I) CO1A2_HUMAN 129 1  0 3  0 0.0130
Collagen alpha-1(III) CO3A1_HUMAN 139 ND 1  0 0.3900
Proteomics of Abdominal Aortic Aneurysms
Molecular & Cellular Proteomics 10.8 10.1074/mcp.M111.008128–7
TABLE II
Extracellular matrix and associated proteins identified by proteomics in the 4 M guanidine extracts. aThree biological samples performed with
two technical replicates each (n  6). bFour biological samples performed with two technical replicates each (n  8). cIndicates proteins
identified for the first time by proteomics in the vasculature. ND: none detected
Protein name
Swiss Prot
Accession
MW
(kDa)
Mean
spectraS.E.
CONa
Mean
spectraS.E.
AAAb
p value
(t-test)
Proteoglycans and glycoproteins
Fibronectin FINC_HUMAN 263 210  15 336  16 0.0001
Perlecan PGBM_HUMAN 469 323  13 176  43 0.0280
Versican CSPG2_HUMAN 373 190  5 84  18 0.0010
Aggrecan PGCA_HUMAN 250 154  23 28  11 0.0003
Prolargin PRELP_HUMAN 44 76  8 86  8 0.3100
Tenascin TENA_HUMAN 241 11  1 144  21 0.0001
Biglycan PGS1_HUMAN 42 74  4 78  10 0.4400
Vitronectin VTNC_HUMAN 54 26  2 117  12 0.0001
Decorin PGS2_HUMAN 40 35  7 70  14 0.0430
Clusterin CLUS_HUMAN 52 34  2 69  7 0.0001
Periostin POSTN_HUMAN 93 56  6 47  6 0.6400
Lactadherin MFGM_HUMAN 43 60  12 39  11 0.2400
Lumican LUM_HUMAN 38 41  2 51  6 0.1400
Thrombospondin-1 TSP1_HUMAN 129 2  1 90  12 0.0001
Tenascin-X TENX_HUMAN 464 31  1 39  10 0.3600
Nidogen-1 NID1_HUMAN 136 29  4 24  7 0.6700
Aortic carboxypeptidase-like protein AEBP1_HUMAN 131 21  2 28  6 0.2900
Laminin subunit gamma 1 LAMC1_HUMAN 178 26  6 16  6 0.3300
Mimecan MIME_HUMAN 34 15  2 23  8 0.3200
Laminin subunit beta 2 LAMB2_HUMAN 196 23  4 12  4 0.0960
Dermatopontin DERM_HUMAN 24 17  5 16  3 0.8100
Annexin A2 ANXA2_HUMAN 39 13  2 19  5 0.2600
Hyaluronan and proteoglycan link protein 1 HPLN1_HUMAN 40 25  9 6  2 0.0510
Fibrillin-1 FBN1_HUMAN 312 4  1 26  4 0.0001
Laminin subunit alpha 5 LAMA5_HUMAN 400 19  4 6  2 0.0060
Fibulin-5 FBLN5_HUMAN 50 14  3 3  1 0.0110
Metalloproteinase inhibitor 3 TIMP3_HUMAN 24 3  1 14  3 0.0067
Galectin-1 LEG1_HUMAN 15 9  3 8  2 0.9900
Asporin ASPN_HUMAN 43 2  1 12  5 0.0800
EMILIN-1 EMIL1_HUMAN 107 8  3 3  1 0.1700
Microfibril-associated glycoprotein 4 MFAP4_HUMAN 29 9  2 2  1 0.0120
Nidogen-2 NID2_HUMAN 151 2  0 7  3 0.0630
Fibromodulin FMOD_HUMAN 43 5  2 3  0 0.3700
Fibulin-1 FBLN1_HUMAN 77 6  2 1  0 0.0110
Agrin AGRIN_HUMAN 215 4  2 3  1 0.5700
Thrombospondin-2 TSP2_HUMAN 130 ND 7  1 0.0001
Microfibrillar-associated protein 5 MFAP5_HUMAN 20 3  1 3  1 0.5400
Glia-derived nexin GDN_HUMAN 44 ND 4  1 0.0014
Laminin subunit beta 1 LAMB1_HUMAN 198 ND 4  1 0.0110
RPE-spondin RPESP_HUMAN 30 4  2 1  1 0.0330
Podocan PODN_HUMAN 69 ND 3  1 0.0700
Matrix Gla proteinc MGP_HUMAN 12 1  0 1  1 0.7500
Sclerostin SOST_HUMAN 24 1  0 ND 0.1800
SPARC-like protein 1c SPRL1_HUMAN 75 1  1 ND 0.1100
Cartilage oligomeric matrix protein COMP_HUMAN 83 1  1 ND 0.0930
Matrilin-2 MATN2_HUMAN 107 1  0 1  1 0.7900
Galectin-3 LEG3_HUMAN 26 1  1 ND 0.2700
Spondin-1 SPON1_HUMAN 91 1  1 ND 0.1300
Cartilage acidic protein 1c CRAC1_HUMAN 71 ND 1  1 0.2100
SPARC-related modular calcium-binding protein 2 SMOC2_HUMAN 50 1  0 ND 0.3200
Fibronectin type III domain-containing protein 1 FNDC1_HUMAN 205 1  0 ND 0.2300
Laminin subunit alpha 4 LAMA4_HUMAN 203 1  0 ND 0.3000
Hemicentin-1 HMCN1_HUMAN 613 ND 1  0 0.4100
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TABLE II—continued
Protein name
Swiss Prot
Accession
MW
(kDa)
Mean
spectraS.E.
CONa
Mean
spectraS.E.
AAAb
p value
(t-test)
ECM-associated proteins
Serum amyloid P component SAMP_HUMAN 25 39  6 91  20 0.0220
Apolipoprotein B-100 APOB_HUMAN 516 ND 96  34 0.0470
Apolipoprotein A-I APOA1_HUMAN 31 ND 50  16 0.0230
Serine protease HTRA1 HTRA1_HUMAN 51 16  4 19  7 0.7600
TGF-beta induced protein ig-h3 BGH3_HUMAN 75 8  3 27  4 0.0001
Insulin-like growth factor-binding protein 7 IBP7_HUMAN 29 20  2 9  3 0.0430
EGF-containing fibulin-like extracellular matrix
protein 1
FBLN3_HUMAN 55 13  2 12  5 0.9900
Cathepsin D CATD_HUMAN 22 8  2 14  4 0.1090
Extracellular superoxide dismutase SODE_HUMAN 26 18  3 5  2 0.0020
Target of Nesh-SH3 TARSH_HUMAN 119 20  4 3  1 0.0002
Metalloproteinase inhibitor 3 TIMP3_HUMAN 24 3  1 14  3 0.0067
Apolipoprotein E APOE_HUMAN 36 ND 15  4 0.0180
Macrophage metalloelastasec MMP12_HUMAN 54 ND 15  3 0.0033
Apolipoprotein D APOD_HUMAN 21 ND 13  2 0.0035
Latent-transforming growth factor beta-binding
protein 2
LTBP2_HUMAN 195 9  2 4  1 0.0570
Latent-TGF-beta binding protein, isoform 1S LTB1S_HUMAN 153 8  2 4  2 0.3000
Ceruloplasmin CERU_HUMAN 122 ND 12  5 0.0650
Transforming growth factor beta-1-induced
transcript 1 protein
TGFI1_HUMAN 50 10  2 1  1 0.0003
Cathepsin G CATG_HUMAN 29 3  2 7  2 0.0450
Chymase CMA1_HUMAN 27 7  1 3  2 0.2700
Myeloperoxidase PERM_HUMAN 84 ND 10  3 0.0210
Neutrophil defensin 1 DEF1_HUMAN 10 1  1 9  1 0.0003
LIM and cysteine-rich domains protein 1 LMCD1_HUMAN 41 9  2 ND 0.0067
Lysyl oxidase homolog 1 LOXL1_HUMAN 63 5  2 3  1 0.2900
Galectin-3-binding protein LG3BP_HUMAN 65 6  3 2  0 0.1000
Tryptase beta-1 TRYB1_HUMAN 31 4  1 3  2 0.9900
Metalloproteinase inhibitor-3 TIMP1_HUMAN 23 ND 6  2 0.0270
Pigment epithelium-derived factor PEDF_HUMAN 46 2  1 3  1 0.6100
Carboxypeptidase-like protein X2 CPXM2_HUMAN 86 4  2 ND 0.1600
Apolipoprotein A-IV APOA4_HUMAN 45 ND 4  3 0.1900
Phospholipase A2, membrane associated PA2GA_HUMAN 16 2  1 2  1 0.9300
Apolipoprotein L1 APOL1_HUMAN 44 ND 4  2 0.1900
Protein S100-A9c S10A9_HUMAN 13 ND 4  1 0.0290
Latent-transforming growth factor beta-
binding protein 4
LTBP4_HUMAN 173 3  1 ND 0.0550
Procollagen C-endopeptidase enhancer 1 PCOC1_HUMAN 48 2  1 ND 0.1700
Kallistatin KAIN_HUMAN 49 ND 2  2 0.3300
Properdin PROP_HUMAN 51 1  1 1  0 0.7500
Calreticulin CALR_HUMAN 48 1  1 1  0 0.2900
Antileukoproteinase SLPI_HUMAN 14 1  0 ND 0.0980
Cathepsin Z CATZ_HUMAN 34 1  1 ND 0.4800
Secreted frizzled-related protein 1 SFRP1_HUMAN 35 2  1 ND 0.1200
SPARC-like protein 1 SPRL1_HUMAN 75 1  1 ND 0.1100
Protein S100-A8c S10A8_HUMAN 11 1  0 1  0 0.4200
Secreted frizzled-related protein 3 SFRP3_HUMAN 36 1  1 ND 0.1400
C-type lectin domain family 11 member Ac CLC11_HUMAN 36 1  0 1  0 0.9500
Lipocalin 1c LCN1_HUMAN 19 ND 1  0 0.1800
Secreted phosphoprotein 24 SPP24_HUMAN 24 ND 1  1 0.1600
EGF-like repeat and discoidin I-like domain-
containing protein 3 EDIL3_HUMAN 54 ND 1  1 0.2400
Insulin-like growth-factor binding protein complex
acid labilec
ALS_HUMAN 66 ND 1  0 0.2900
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Changes in the Extracellular Proteome of AAA—Proteomics
revealed marked differences in the ECM composition be-
tween control and AAA specimens (Figs. 4 and 5). As a
consequence of the pathological remodeling, the salt-soluble
protein fraction of aneurysms was enriched in ECM fragmen-
tation products. Many of the identified protein changes have
not been previously reported in AAA, including collagen XII,
thrombospondin 2, periostin, and ACLP. Collagen XII is a
fibril-associated collagen and accumulates in tissues exposed
to high tensile forces (31) whereas periostin and thrombos-
pondin 2 are glycoproteins involved in cellular adhesion and
spreading (32, 33). ACLP is an extracellular glycoprotein,
which is known to accumulate in the ECM associated with
collagen fibers (29), but its function is not well understood.
Recently, Schissel et al., showed that ACLP is a positive
regulator of fibrosis in the injured lung (34). Fibronectin is the
TABLE II—continued
Protein name
Swiss Prot
Accession
MW
(kDa)
Mean
spectraS.E.
CONa
Mean
spectraS.E.
AAAb
p value
(t-test)
Collagens
Collagen alpha 3(VI) CO6A3_HUMAN 344 194  35 343  37 0.0025
Collagen alpha 1(VI) CO6A1_HUMAN 109 74  10 95  16 0.1100
Collagen alpha 1(XIV) COEA1_HUMAN 194 112  17 40  9 0.0005
Collagen alpha 1(XVIII) COIA1_HUMAN 178 69  6 13  4 0.0001
Collagen alpha 1(I) CO1A1_HUMAN 139 36  5 41  2 0.0580
Collagen alpha 1(XII) COCA1_HUMAN 333 17  3 60  10 0.0006
Collagen alpha 2(VI) CO6A2_HUMAN 109 35  6 40  7 0.2400
Collagen alpha 2(I) CO1A2_HUMAN 129 34  2 36  2 0.0580
Collagen alpha 2(IV) CO4A2_HUMAN 168 37  6 31  12 0.7700
Collagen alpha 1(XV) COFA1_HUMAN 142 24  6 17  5 0.4300
Collagen alpha 1(V) CO5A1_HUMAN 184 8  1 11  2 0.0300
Collagen alpha 1(VIII) CO8A1_HUMAN 73 7  2 9  3 0.6200
Collagen alpha 2(VIII) CO8A2_HUMAN 67 2  1 3  1 0.3100
Collagen alpha 1(IV) CO4A1_HUMAN 161 1  1 2  1 0.4700
Collagen alpha 1(XXI) COLA1_HUMAN 99 1  0 2  1 0.2100
Collagen alpha 2(V) CO5A2_HUMAN 145 ND 1  0 0.0820
FIG. 3. Differential solubility of extracellular proteins. A, The Venn diagram displays the number of ECM and associated proteins extracted
with either 0.5 M NaCl or 4 M guanidine. The SwissProt entry codes of uniquely identified proteins are given for each extract. All identifications
are listed in Tables I and II. B, In the 0.5 M NaCl extracts the spectral counts for ECM proteins were significantly increased in the AAA samples
in comparison to control aortas (CON). The total number of identified spectra was similar. C, In the 4 M guanidine extracts neither the spectral
counts for ECM proteins nor the total number of spectra were significantly different between controls and AAA. Values are mean  S.E. *** p 
0.001. Statistical analysis was performed using 2-tailed, unpaired t test.
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primary component of granulation tissue after wound healing
(35) and this may explain its accumulation in the injured aortic
wall. Increased tenascin mRNA expression has been previ-
ously reported in AAA and was associated with the accumu-
lation of macrophages (36). Our proteomics data also re-
vealed the fragmentation of these ECM proteins (Fig. 5).
Degradation products reflect the pathological remodeling
process in AAA.
In the 4 M guanidine extracts of AAA there was a reduction
in the three major proteoglycans versican, perlecan, and ag-
grecan, as well as link protein, the glycoprotein which links
aggregating proteoglycans to hyaluronic acid. Although a pre-
vious study demonstrated that versican was reduced in an-
eurysms (37), not much is known about the contribution of
perlecan and aggrecan to this pathology (38, 39). The loss of
these major proteoglycans is likely to have major impact on
SMC attachment, proliferation, and migration but it will also
affect the binding and storage of various regulatory molecules
in the extracellular space including extracellular enzymes and
growth factors (40). For example, extracellular superoxide
dismutase (eSOD) was reduced in AAA (Fig. 5). This potent
antioxidant enzyme is located in the vascular extracellular
space bound to subendothelial heparan sulfate proteoglycans
such as perlecan (21). A loss of these proteoglycans could
result in reduced retention of eSOD and other extracellular
proteins, thereby affecting the overall integrity of the vascular
wall.
MMP-12 in AAA—Studies investigating the proteolytic ac-
tivity in human tissues rely on mRNA expression, immuno-
staining or zymography and tend to focus on individual pro-
teinases and their inhibitors. MMPs -1, -2, -3, -7, -9, and -12
have previously been detected in macrophage-rich areas of
AAA and their proteolytic activity has been linked to aneurysm
formation (24–26). Interestingly, little is known about their
relative abundance in AAA. A limitation of antibody-based
detection is that the staining intensity is not only dependent
on the protein amount but also on the binding affinity and
specificity of the antibody. Hence, staining with different an-
FIG. 4. Hierarchical clustering of extracellular proteins. The dendrograms display hierarchical clustering analysis (Pearson correlation
coefficient) of the differentially expressed extracellular proteins in the 0.5 M NaCl extracts (A) and in the 4 M guanidine extracts (B). “R”
denotes the technical replicate obtained for each clinical sample using the RePlay device. Differences in spectral counts are color-coded
as indicated.
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tibodies cannot be directly compared. Instead, a proteomics
approach provides an unbiased assessment of proteinases
and potential degradation products in diseased tissue.
Whereas previous proteomics studies primarily focused on
cellular proteins and failed to identify MMPs in AAA (8, 9), our
subfractionation method enabled the detection of MMP-12.
This does not exclude the presence of other MMPs, but
suggests that MMP-12 is probably more abundant and un-
derscores its role in the pathology of AAA (41, 42). MMP-2,
cathepsins D, G, S, and Z, and the mast cell proteinases
FIG. 5. Validation of ECM remodeling markers. The spectral counts (left panels) for collagen XII, tenascin, thrombospondin 2, fibronectin
and ACLP (alternative name: adipocyte enchancer-binding protein 1; AEBP-1) were significantly higher in the 0.5 M NaCl extracts of AAA
compared with controls. Values are mean  S.E. *** p  0.001, ** p  0.01, ** p  0.05, ns not significant. Statistical analysis was performed
using two-tailed, unpaired t test. Immunoblotting (middle panels) confirmed increased levels as well as fragmentation of these ECM proteins
in AAA. The loss of eSOD and the accumulation of MMP-12 and TIMP-1 in AAA were also validated by immunoblotting. Arrows indicate the
expected molecular mass of full-length proteins. With the exception of periostin and MMP-12, there was a high correlation (Spearman
correlation r  0.8, p  0.05) in protein abundance determined by spectral counting and Western blotting (right panels).
FIG. 6. Novel MMP-12 targets. A, The color-coded heat map demonstrates the number of identified spectra for the 6 glycoproteins in the
0. 5 M NaCl extracts in control and AAA samples and their molecular weight distribution after SDS-PAGE. B, A normal aortic specimen was
dissected into three equal blocks and treated with either 50 pM MMP-9, 50 pM MMP-12, or left untreated (CON) in MMP reaction buffer for 24 h
at 37 °C. The resulting supernatants were analyzed by immunoblotting for collagen XII, tenascin, thrombospondin 2 (TSP2), fibronectin, ACLP,
and periostin. Arrows indicate proteolytic fragments generated by MMP-12 treatment. C, 10 g human purified fibronectin and 10 g human
recombinant periostin and TSP2 were incubated for 16h at 37 °C either in plain MMP reaction buffer or supplemented with 50 pM MMP-12
(MMP-12). The protein mixtures were separated by one-dimensional SDS-PAGE and stained in a 0.05% w/v Coomasie G-250, 5% v/v glacial
acetic acid solution to monitor substrate degradation.
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chymase and tryptase -1 were also identified (Table I and
Table II), but only cathepsin G was significantly increased in
AAA (Fig. 4B). Interestingly, cathepsin G was recently shown
to degrade intraluminal thrombi in aneurysms (43).
Novel Targets of MMP-12 in the Aortic Tissue—Apart from
its well-established elastolytic and collagenolytic properties
(24), little is known about the ability of MMP-12 to degrade
other substrates in the aorta. Thus far, the presence of pro-
teolytic products from known MMP targets has been mainly
studied by immunostaining using neoepitope antibodies
against the cleaved substrates (44). Our subfractionation
methodology allowed a more comprehensive analysis of the
ECM remodelling in AAA. For instance, in the salt-soluble
protein fraction, we observed not only an increase but also a
partial degradation of collagen XII, fibronectin, tenascin,
thrombospondin 2, ACLP, and periostin. When healthy aortic
tissue was incubated with recombinant MMP-12, the pro-
teinase was able to cleave these substrates. Its effect, at
least in vitro, was more potent than MMP-9, suggesting that
MMP-12 might be responsible for the degradation of these
proteins in AAA. Of course, the fragmentation pattern after
MMP-12 treatment was not identical to the laddering ob-
served in the 0.5 M NaCl extracts. This is expected because
the proteolytic activity in tissues is a highly dynamic process
regulated by the interplay of MMPs with TIMPs and other
inhibitors. In agreement with previous studies (45), we found
that TIMP-1 and -3 were significantly increased in AAAs
(Figs. 4A and 4B) indicating a compensatory anticatabolic
response. One of the fragmented proteins in AAA was ACLP
(Fig. 5). MMP-12 was able to degrade it in vitro (Fig. 6B).
Further analysis by immunohistochemistry confirmed an in-
verse correlation of the staining intensities for ACLP and
MMP-12 in the inflammatory regions of AAA (Figs. 7B and
7D), providing additional evidence that the proteinase could
target ACLP in vivo.
Strengths and Limitations—The gel-based separation em-
ployed in this study, preserves the molecular mass of proteins
and allows the assessment of proteolytic degradation in dis-
eased tissues. This key information on protein fragmentation
is lost in conventional shotgun proteomics. The label-free
quantitation based on spectral counting allows the relative
estimation of protein abundance (46) and shows a good cor-
relation with approaches based on isotopic labels (47) and
precursor peak area intensity measurements (23). However,
FIG. 7. Immunohistochemical staining for ACLP and MMP-12. Consecutive serial sections of AAA tissue were stained with antibodies to
ACLP (A and B) or MMP-12 (C and D). ACLP was found in both the hypocellular areas with the remaining elastic laminae (A) and in the
amorphous, inflammatory regions of the media with evidence of connective tissue destruction (B). MMP-12 was predominantly found in the
inflammatory regions (D). Positive immunostaining is indicated by brown color obtained with diaminobenzidine (DAB) development of
horseradish peroxidase-conjugated secondary antibodies. Negative controls were incubated with isotype control antibodies (E and F). Nuclei
were counterstained with Mayer’s hematoxylin. 20X magnification. Scale bar: 25 m.
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its accuracy is limited to large differences and proteins with
reasonable abundance. Hence, caution should be taken in the
interpretation of modest changes and the quantitation of
scarce proteins (48). In this study we analyzed simplified
subproteomes and nine extracellular proteins were validated
by Western blotting to ensure the accuracy of our proteomics
findings. The observed changes between healthy and aneu-
rysmal tissues were pronounced allowing reliable conclusions
to be made despite the low number of clinical specimens
available. Because AAAs are currently treated by endovascu-
lar stenting rather than open repair interventions, surgical
specimens are increasingly rare. Additionally, healthy control
tissue could only be obtained from the thoracic part of the
aorta.
Conclusion—This study is the first to employ a solubility-
based extraction procedure to study the ECM composition in
human AAA by proteomics. Our methodology led to the iden-
tification of novel candidate markers of pathological tissue
remodeling and identified new proteolytic targets of MMP-12,
one of the key proteinases in AAA.
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